hyun_seoul said:The mechanism that matters here is not stomach emptying, it is central.
This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.
Adding the clinical framing, because it changes how the question reads.
I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.
My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.
14 months later: down 41 lbs, off lisinopril, A1C from 8.2% to 5.4%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.
traveltech_sara said:The dose-response is real but shallow at the top.
Pushing back on traveltech_sara here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
I would rather be corrected than agreed with, if it comes to it.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.NateNeph said:SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…
6 month update on cardiovascular risk: down 48 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.
Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Thread quality here is what the rules are for. Keep it up.